What Are the Long-Term Side Effects of Imatinib Treatment?

Imatinib, most widely known by the brand name Gleevec, transformed chronic myeloid leukemia (CML) from a near-fatal diagnosis into a manageable chronic condition. But “manageable” does not mean side-effect free, and because many patients take imatinib for a decade or longer, even mild toxicities can accumulate into problems that reshape daily life. The most common long-term complaints are chronic fatigue, musculoskeletal pain, fluid retention, and a slow decline in kidney function, though a wider constellation of effects on the heart, liver, bones, blood counts, and even cognition has been documented over years of follow-up.

Fatigue and Its Ripple Effects on Daily Life

If you ask patients on long-term imatinib what bothers them most, fatigue tops the list. A study of CML patients found that fatigue was the only variable that independently and consistently dragged down both physical and mental quality-of-life scores. The gap between patients with low fatigue and those with high fatigue was enormous: more than eight times what clinicians consider a meaningful difference on the physical role scale and seven times on the emotional scale.¹ Fatigue does not travel alone. It correlates strongly with musculoskeletal pain and muscle cramps, creating a cluster of symptoms that can make even routine activities feel heavy.²

Patients treated for gastrointestinal stromal tumors (GIST) report a similar pattern: fatigue, facial edema, and muscle cramps are the side effects that hit quality of life hardest, regardless of whether the drug is being used in an early or advanced-disease setting.² This is worth emphasizing because fatigue from imatinib is often dismissed as “just tiredness.” For many patients, it is the single biggest barrier between them and the life they had before treatment.

Kidney Function Can Decline Gradually

One of the more under-discussed long-term effects is a slow erosion of kidney function. An early study of CML patients found that estimated kidney filtration rate dropped by roughly 2.8 mL/min per year of imatinib use, and about 12% of patients developed chronic renal failure over the course of treatment.³ A more recent analysis confirmed that imatinib produces a decline in kidney function comparable to what you see in early-stage chronic kidney disease, with elderly patients and those who already have high blood pressure or a lower starting filtration rate at greatest risk.⁴

The picture is not perfectly consistent across studies. At least one analysis did not find a statistically significant change in kidney filtration over time among imatinib-treated patients, though the study was smaller.⁵ The weight of the evidence, though, points toward a real and clinically meaningful decline, especially in patients who are already older or have kidney-related risk factors. Regular monitoring of kidney function is now considered standard practice for anyone on imatinib for more than a couple of years.

Cardiovascular Concerns

Imatinib has been linked to congestive heart failure and reduced heart-pumping ability in a subset of patients. Laboratory work suggests the damage stems from disruption of the heart muscle cells’ internal cleanup systems and stress on a key cellular structure, rather than from the drug’s intended cancer-fighting mechanism.⁶ Animal studies have added detail: in mice, imatinib caused heart cell loss and weakened cardiac function, and the damage was significantly worse in older animals, partly because aging raises oxidative stress in heart tissue.⁷

That said, this is one area where imatinib actually compares favorably to its newer competitors. In a ten-year head-to-head trial, cardiovascular events occurred in only about 6% of imatinib-treated patients at ten years, compared to roughly 25% and 33% for two different doses of nilotinib, a second-generation drug in the same class.⁸ So while heart toxicity from imatinib is real and worth watching for, the drug carries a substantially lower cardiovascular burden than several alternatives. Patients who are older or have pre-existing heart conditions should discuss monitoring with their oncologist.

Anemia and Other Blood Count Problems

Imatinib suppresses the bone marrow, which is expected given that the drug targets a cancer of blood-forming cells. Anemia is the most persistent hematologic side effect over the long term. In one large cohort, roughly two-thirds of imatinib-treated patients developed anemia, and while some responded well to treatment with erythropoietin (a hormone that stimulates red blood cell production), patients who had anemia alongside other blood count drops fared worse overall.⁹

A Brazilian study tracking long-term anemia found that after two years on imatinib, about 80% of patients had some degree of anemia. Roughly a third of those patients saw their blood counts normalize spontaneously over time, but the majority continued to have lower-than-normal hemoglobin levels at their last follow-up.¹⁰ Drops in white blood cells and platelets also occur, but data from a Kenyan cohort showed these generally improve within the first one to three years and often resolve, unlike anemia, which can linger.¹¹

Fluid Retention, Skin Changes, and Periorbital Edema

Puffiness around the eyes is one of the most visible and annoying side effects, and it does not fade as quickly as patients hope. In one series, about 70% of patients developed periorbital edema, and roughly 18% experienced excess tearing.¹² More general fluid retention, including edema in the limbs and weight gain, is common enough to be considered a class effect of the drug.¹³ Skin rashes and depigmentation also show up on the list of recognized long-term complaints.

Less commonly, more serious eye issues have been reported. Optic disc edema, a swelling of the nerve at the back of the eye, has appeared in case reports, which is a reminder that the well-known puffiness around the eyes is the mild end of a spectrum.¹⁴ If you experience changes in vision beyond the cosmetic annoyance of swollen eyelids, that warrants a prompt conversation with your doctor.

Liver Toxicity

Liver problems from imatinib range from mildly abnormal blood tests that your oncologist flags on routine panels to serious liver damage in rare cases. Hepatotoxicity can present as elevated liver enzymes, hepatitis, and, in extreme situations, acute liver failure.¹⁵ There is also a concern about reactivation of hepatitis B in carriers. At least one documented case involved liver cirrhosis developing in a GIST patient during imatinib treatment, suggesting that acute liver injury can sometimes progress to chronic scarring if not caught.¹⁶ Patients who develop significant liver enzyme elevations during treatment should be carefully evaluated for underlying chronic liver disease, because the damage may not stop when the enzyme numbers improve.

Bone and Mineral Metabolism

Imatinib has an unusual dual personality when it comes to bone. On one hand, it promotes new bone formation. A study of CML patients found that more than half showed at least a twofold increase in trabecular bone volume after starting imatinib. At the same time, the drug significantly lowered blood levels of phosphate and calcium, with low phosphate (hypophosphatemia) becoming evident in a sizable proportion of patients.¹⁷ Lab experiments confirmed the bone-building effect was dose-dependent, with higher concentrations of imatinib producing more mineralization.

The clinical meaning of these changes is a bit complicated. The increased bone formation sounds like good news, especially for older patients who might otherwise be losing bone density. But the drop in phosphate can cause its own problems, including muscle weakness and fatigue, which may contribute to the symptom burden patients feel. The overall bone-health picture on imatinib is an active area of investigation, and monitoring phosphate and calcium levels is advisable during long-term use.

Growth Impairment in Children

For pediatric patients, the most worrisome long-term side effect is stunted growth. Children treated with imatinib show a progressive decline in height relative to their age-matched peers. In a German cohort, height scores dropped significantly within the first year and continued to fall through the second year of treatment.¹⁸ Prepubertal children are hit hardest, at least initially: in the first year of treatment, the decline in height was roughly twice as steep in younger children compared to those who had already entered puberty.¹⁹

A prospective study from India added troubling long-term data. Among patients on imatinib for more than two years, about 15% had short stature, and the vast majority of those had started treatment before puberty. Even more striking, when the researchers looked at older patients with short stature, these individuals had never caught up to their expected height, suggesting the growth impairment is not just a delay but a permanent loss of height potential. None of the short-stature patients had growth hormone deficiency, which means the problem is not a simple hormonal one that a supplement could fix.²⁰ For families with children on imatinib, tracking growth closely and discussing timing of treatment with a pediatric oncologist matters.

Cognitive and Psychological Effects

Patients on imatinib and similar targeted therapies report worse cognitive function than healthy controls, and the gap is not subtle. In a controlled comparison, treated patients scored meaningfully lower on self-reported measures of global cognitive function and satisfaction with their own thinking abilities. They also reported worse functioning in five of six specific cognitive areas, including memory, language, planning, organizing, and divided attention.²¹ Fatigue, insomnia, and depressive symptoms all correlated with worse subjective cognition, which fits the picture of a treatment that broadly wears on the nervous system rather than attacking one specific brain function.

This is an area where the science is still catching up to what patients have been saying for years. “Chemo brain” has been extensively studied in traditional chemotherapy, but cognitive complaints from targeted therapies like imatinib received less attention until recently. The available evidence suggests these complaints are real, consistent, and probably intertwined with the fatigue and sleep disruption the drug causes.

Secondary Cancers

One question that hangs over any long-term cancer therapy is whether the treatment itself raises the risk of new, unrelated cancers. Two large studies, one Italian and one German, looked at this in CML patients treated with imatinib and reached broadly reassuring conclusions. In the Italian cohort, about 6% of patients developed a second cancer after a median follow-up of roughly six years, but this rate was not higher than what would be expected in the general population of the same age and sex.²² The German study found second cancers in about 4% of patients and likewise reported no overall increase compared to the general population.²³

There are two important caveats. First, the German data showed a significantly increased rate of non-Hodgkin lymphoma in both male and female imatinib-treated patients, even though the overall cancer rate was normal.²³ Second, the Italian study found that when patients did develop a second cancer, they died from it at a higher-than-expected rate, particularly among women. About half of the patients who got a second cancer died from it, and the death rate from secondary cancers in women was more than twice what would be expected in the general population.²² So while imatinib does not seem to cause more second cancers, the cancers that do occur may behave more aggressively, or patients may be more vulnerable to them.

Infections and Immune Function

Imatinib affects certain immune cells, which raises the theoretical question of whether long-term users face more infections. Fortunately, the rates appear modest. In a series of 250 CML patients followed for a median of several years, about 14% experienced an infection serious enough to require antibiotics or antivirals and a pause in imatinib. Herpes zoster (shingles) and pneumonia were the most common culprits. Patients who developed shingles tended to have lower lymphocyte counts at the time of the infection, suggesting the drug’s suppression of certain white blood cells is the trigger.²⁴ The infection rate is low enough that most oncologists do not prescribe prophylactic antibiotics or antivirals, but patients should know that shingles in particular is worth watching for.

Reproductive Risks

Imatinib is known to be harmful during pregnancy and is classified as a drug that should be avoided by women who are or could become pregnant. Animal research has taken this a step further by suggesting that even past exposure to the drug can leave lasting effects on reproductive outcomes. In mice, females that had been treated with imatinib and then allowed a washout period before mating still had smaller litter sizes, more fetal loss, reduced placenta size, and changes in the chemical tagging of genes important for embryo development.²⁵ These are animal findings, and they may not translate directly to humans, but they underline why discussions about fertility planning should happen early in treatment and why post-treatment conception timing should involve specialist input.

What Happens When You Stop

For patients who achieve a deep and sustained remission, discontinuing imatinib is sometimes possible, and it comes with its own unexpected twist. About 30% of patients in one study developed new or worsened musculoskeletal pain and itching after stopping the drug, a phenomenon known as imatinib withdrawal syndrome.²⁶ The pain can be quite bothersome. Standard painkillers and anti-inflammatory drugs help in mild cases, and steroids may be needed for more severe episodes. The symptoms do eventually resolve in essentially all patients, though it can take many months. In one series, resuming imatinib promptly eliminated the symptoms, but understandably most patients are not eager to restart a drug they just stopped.²⁷

Interestingly, patients who develop withdrawal syndrome are actually more likely to stay in remission after stopping. That association hints that the immune system’s reactivation upon drug withdrawal, the same process that causes the joint pain, may be helping to keep the leukemia in check.²⁶

Tolerability Over a Decade of Use

Long-term follow-up from the landmark IRIS trial, which first proved imatinib’s superiority, offers a bird’s-eye view of how patients do over many years. Among patients initially assigned to imatinib, about 48% completed treatment on the drug. Around 16% switched off because it was not working well enough, and about 7% stopped because of side effects.²⁸ That 7% figure is often cited as evidence that imatinib is well tolerated relative to older therapies, and it is: in the same trial, only about 1% of patients on the previous standard treatment (interferon plus cytarabine) even completed their assigned regimen. But for the patients who are among that 7%, and for the many more who continue treatment while managing chronic symptoms, the side effects are a daily reality rather than a reassuring statistic.

The practical takeaway is that imatinib is simultaneously one of the greatest success stories in cancer medicine and a drug with a genuine long-term symptom burden. Most of the serious toxicities, including heart and liver damage, are uncommon, but the chronic, lower-grade effects like fatigue, muscle cramps, fluid retention, and slow kidney decline are widespread enough that they deserve proactive monitoring and open conversations between patients and their care teams.